Role of IL-37 in Cardiovascular Disease Inflammation

Ziyi Yang,Lin Kang,Yan Wang,Jiaqing Xiang,Qianying Wu,Cong Xu,Yanqing Zhou,Shaoyuan Chen,Hongcheng Fang,Jie Liu,Ming Dong
DOI: https://doi.org/10.1016/j.cjca.2019.04.007
IF: 6.614
2019-01-01
Canadian Journal of Cardiology
Abstract:Inflammation is closely related to the pathogenesis and prognosis of cardiovascular disease (CVD). Interleukin-37 (IL-37), an anti-inflammatory IL-1 family cytokine, shifts cytokine expression from pro- to anti-inflammation via regulation of macrophage polarization and lipid metabolism. In macrophages, IL-37 functions through both intracellular and extracellular pathways to regulate the activity of NF-kB and PTEN as well as the expression of cytokines, including IL-1β, IL-6, and IL-10. Moreover, IL-37 levels are increased in the serum of patients with heart failure, atherosclerosis, and acute coronary syndrome with no evidence of anti-inflammatory effects. However, transgenic overexpression of IL-37 improves cardiac infarct and attenuates atherosclerosis plaque expansion. Hence, it is worthwhile to investigate the precise mechanism and role of IL-37 in the pathogenesis of CVD, which may provide deeper understanding of the inflammatory response in this context. This review summarizes the regulatory role of IL-37 in systematic inflammation induced by CVD and highlights recent advancements in the clinical application of IL-37 as a therapeutic agent or biomarker for diagnosis of CVD.
What problem does this paper attempt to address?